Visual Abstract

Background: This study presents real-world effectiveness of sema OW in a cohort of US commercially insured/Medicare Advantage T2D patients newly initiating a GLP-1 agonist.

Methods: Claims and lab result data were used to identify T2D patients who initiated sema OW between 12/1/17 - 6/30/20 (index as first claim). Selected patients had ≥1 A1c result within ≤3 months pre- and ≥3 months post-index. Patients with no claim for any GLP-1 agonist in the 12 months prior to index and persistent on sema OW (those with a sema OW prescription with days supply dispensed overlapping/in proximity of date of post-index A1c) were assessed for A1c changes and stratified by age (</≥ 65 years) and those with pre-index A1c >9%.

Results: Of 1,842 patients newly initiating sema OW, 49% were female and 8% were ≥ 65 years of age. The pre/post change in A1c was significant in all patients (-1.3%) and in each age subgroup (<65 years = -1.3%; ≥ 65 years = -1.2%; all p<0.001, Figure 1). Significant A1c reductions of ≥ 2.2% were observed in all patients with pre-index A1c >9%, regardless of age. Attainment of A1c <7% and <8% increased from 20% to 56% and from 46% pre-to 80% post-index for all patients, respectively (both p<0.001).

Conclusion: nitiation of sema OW in T2D patients naïve to GLP-1 agonists and persistent on sema OW was associated with a significant reduction in A1c and an increase in target attainment of A1c <7% and <8% across all age groups.

Disclosure

N. Shivappa: Other Relationship; Self; Novo Nordisk. C. Swift: Employee; Self; Novo Nordisk Inc. J. Noone: Employee; Self; Novo Nordisk Inc. S. Du: None. Y. M. Paprocki: Employee; Self; Novo Nordisk, Stock/Shareholder; Self; Novo Nordisk. H. Tan: Other Relationship; Self; HealthCore. V. Willey: Employee; Self; HealthCore.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.